Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

4round participations

0lead positions

Oct 2025latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila Sciences—Mar 2025 → Oct 20253 roundsParticipant—

GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:Biomedicines—Nov 2021 → Nov 20211 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Oct 10, 2025LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila SciencesSeries A$350M—Participant

Source ↗

Sep 15, 2025LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila SciencesSeries A$235M—Participant

Source ↗

Mar 10, 2025LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila SciencesSeed$200M—Participant

Source ↗

Nov 18, 2021GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries B$370M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗